Records containing: Triple-negative Breast Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2023-03-29A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)
-
CLINICAL_TRIALS study record update · 2023-03-10Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2023-03-10Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2023-02-21A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2023-01-18Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemotherapy and a Diet Mimicking FASTing Plus/Minus Metformin in the Preoperative Setting: the BREAKFAST Trial
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-08-10Precision Treatment of Refractory Triple Negative Breast Cancer Based on Molecular Subtyping --FUSCC-TNBC- Umbrella Trial
-
CLINICAL_TRIALS study record update · 2022-06-30A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2022-05-13A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2022-05-03GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response
-
CLINICAL_TRIALS study record update · 2022-04-20Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2022-04-18Computed Tomography-based Radiomics of Axillary Lymph Node Pathological Complete Remission (ypN0) in Breast Cancer Undergoing Neoadjuvant Chemotherapy
-
CLINICAL_TRIALS study record update · 2022-02-08A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
-
CLINICAL_TRIALS study record update · 2021-11-15A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2021-08-31A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2021-08-19Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2021-06-02A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2021-06-02A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2021-04-30Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2021-02-11A Single-armed Multicenter Phase Ib / II Study of HX008 (a Recombinant Humanized Anti-PD-1 Monoclonal Antibody) Combined With GP Regimen as the First-line Treatment in Patients With Metastatic Triple Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2020-12-07Chidamide Combined With Neoadjuvant Chemotherapy in Early Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2020-10-30A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2020-04-27Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino Women With Triple-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2019-12-30SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2019-06-07Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
-
CLINICAL_TRIALS study record update · 2019-04-30Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or Metastatic Triple-negative Breast Cancer: a Double-blinded Randomized Controlled Clinical Trial